Project Grant RC2DK140839
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$876K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $324,998 to support the development of advanced stem cell-derived pancreatic islet cell technologies for type 1 diabetes treatment. The key products and services to be delivered include: Assessing the impact of genetically modifying stem cell-derived islet cells to be more resilient to...
This $208,428 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The award will fund research to address key barriers to widespread adoption of islet transplantation, including poor islet survival and engraftment, limited long-term...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $298,364 in funding to Immunoshield Therapeutics Inc. to investigate optimal islet density and dosage within macroencapsulation devices for clinical islet transplantation to treat type 1 diabetes. The research aims to address limitations in current macroencapsulation approaches, such as...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 in funding to The Regents of the University of California, San Francisco (UCSF) to develop an improved preclinical research model for accelerating the translation of therapies for type 1 diabetes (T1D). The goal is to create a stem cell-based multi-cellular platform...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is dedicated to the development and optimization of non-peptide ligands designed to activate insulin receptors. The $772,383 research project aims to transform approaches to glycemic control in the management of diabetes by uncovering a new generation of receptor modulators that could...
This Cooperative Agreement award of $1,232,846.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a vascularized micro-organ platform to study the mechanisms of beta cell death in type 1 diabetes. The key objectives are to: 1) Build a histocompatible system using induced pluripotent stem cells (iPSCs) from type 1 diabetes patients and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $5,079,887 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Benaroya Research Institute at Virginia Mason. The grant aims to investigate whether clonal expansion of islet antigen-reactive T and B cells is an early biomarker of disease activity in Stage 1 type 1 diabetes (T1D). Specifically, the research will leverage expertise in islet...
This $148,568 Project Grant was awarded on January 9, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research conducted by The Leland Stanford Junior University to: 1) Optimize a low-intensity conditioning protocol to generate stable mixed hematopoietic chimerism and induce donor-specific tolerance for allogeneic islet transplantation, and 2)...